- Home
- HNVR vs OCGN Comparison
HNVR vs OCGN Comparison
Compare HNVR & OCGN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- HNVR
- OCGN
- Stock Information
- Founded
- HNVR 2008
- OCGN 2013
- Country
- HNVR United States
- OCGN United States
- Employees
- HNVR N/A
- OCGN N/A
- Industry
- HNVR Commercial Banks
- OCGN Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- HNVR Finance
- OCGN Health Care
- Exchange
- HNVR Nasdaq
- OCGN Nasdaq
- Market Cap
- HNVR 163.2M
- OCGN 189.6M
- IPO Year
- HNVR 2022
- OCGN N/A
- Fundamental
- Price
- HNVR $22.32
- OCGN $0.70
- Analyst Decision
- HNVR Buy
- OCGN Strong Buy
- Analyst Count
- HNVR 1
- OCGN 3
- Target Price
- HNVR $22.00
- OCGN $6.33
- AVG Volume (30 Days)
- HNVR 10.4K
- OCGN 4.2M
- Earning Date
- HNVR 04-16-2025
- OCGN 03-05-2025
- Dividend Yield
- HNVR 1.81%
- OCGN N/A
- EPS Growth
- HNVR N/A
- OCGN N/A
- EPS
- HNVR 1.66
- OCGN N/A
- Revenue
- HNVR $63,491,000.00
- OCGN $4,054,999.00
- Revenue This Year
- HNVR N/A
- OCGN N/A
- Revenue Next Year
- HNVR $16.61
- OCGN N/A
- P/E Ratio
- HNVR $13.64
- OCGN N/A
- Revenue Growth
- HNVR 5.04
- OCGN N/A
- 52 Week Low
- HNVR $13.62
- OCGN $0.52
- 52 Week High
- HNVR $27.14
- OCGN $2.08
- Technical
- Relative Strength Index (RSI)
- HNVR 42.19
- OCGN 53.03
- Support Level
- HNVR $22.29
- OCGN $0.69
- Resistance Level
- HNVR $23.00
- OCGN $0.80
- Average True Range (ATR)
- HNVR 0.97
- OCGN 0.05
- MACD
- HNVR 0.10
- OCGN 0.02
- Stochastic Oscillator
- HNVR 48.00
- OCGN 58.35
About HNVR Hanover Bancorp Inc.
Hanover Bancorp Inc is a United States-based banking company. It offers a full range of financial services and employs a complete suite of consumer and commercial banking products and services, including multi-family and commercial mortgages, residential loans, business loans, and lines of credit.
About OCGN Ocugen Inc.
Ocugen Inc company focused on discovering, developing, and commercializing novel gene and cell therapies and vaccines that improve health and offer hope for patients across the globe. The company's pipeline includes Modifier Gene Therapy Platform, Novel Biologic Therapy for Retinal Diseases, Regenerative Medicine Cell Therapy Platform. The company is developing a modifier gene therapy platform designed to fulfill unmet medical needs related to retinal diseases, including inherited retinal diseases ("IRDs"), such as RP, LCA, Stargardt disease, and multifactorial diseases such as dAMD and Geographic Atrophy ("GA").